top of page

Ferring receives positive CHMP opinion for IVF aid Rekovelle

The Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion for Ferring Pharmaceuticals’ Rekovelle (follitropin delta), recommending that the European Commission grants marketing authorisation for use in controlled ovarian stimulation for the development of multiple follicles in women undergoing assisted reproductive technologies (ART), such as an in vitrofertilisation (IVF) or intracytoplasmic sperm injection (ICSI) cycle.




Today's News
Follow us
  • LinkedIn Social Icon
  • Vimeo Social Icon
Newsletter on Pharma Legislation
the newsletter of
bottom of page